Patents by Inventor Michael Dittgen
Michael Dittgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067623Abstract: [1-Pheny1)-5-(heteroaryl)-1H-pyrazol-3-yl)oxy] acetic acid derivatives and salts thereof, crop protection compositions comprising them, processes for preparing them, use thereof and plant protection compositions. The present invention relates to crop protection compounds and to compositions which comprise specific compounds as safeners for reducing phytotoxic effects of agrochemicals, especially herbicides. The invention relates more particularly to certain [1-(phenyl)-5-(heteroaryl)-1H-pyrazol-3-yl)oxy]acetic acid derivatives of the general formula (I) and their salts, to processes for preparing them and to their use as plant protection compounds (safeners).Type: ApplicationFiled: November 2, 2021Publication date: February 29, 2024Inventors: Thomas MÜLLER, Estella BUSCATO ARSEQUELL, Hendrik HELMKE, Harald JAKOBI, Michael Gerhard HOFFMANN, Jan DITTGEN
-
Publication number: 20170348321Abstract: The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in the mouth preferably in a period of less than 30 min, and the steroid hormone entering the bloodstream transmucosally from the administration system leads to a rapid rise in the concentration in the blood. It is thus possible to achieve a maximum concentration of this steroid hormone in the blood in a period of less than 60 min after administration.Type: ApplicationFiled: August 23, 2017Publication date: December 7, 2017Applicant: LTS Lohmann Therapie-Systeme AGInventors: Markus Krumme, Albert Radlmaier, Sescha General, Michael Dittgen, Keith Jensen
-
Patent number: 9763960Abstract: The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in the mouth preferably in a period of less than 30 min, and the steroid hormone entering the bloodstream transmucosally from the administration system leads to a rapid rise in the concentration in the blood. It is thus possible to achieve a maximum concentration of this steroid hormone in the blood in a period of less than 60 min after administration.Type: GrantFiled: March 28, 2006Date of Patent: September 19, 2017Assignee: LTS Lohmann Theraple-Systeme AGInventors: Markus Krumme, Albert Radlmaier, Sascha General, Michael Dittgen, Keith Jensen
-
Publication number: 20150335658Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: July 29, 2015Publication date: November 26, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Jochen SCHUMACHER, Manfred SUESSE, Michael DITTGEN, Stephan MLETZKO, Jan-Peter INGWERSEN, Thomas LANGGUTH, Dirk SCHENK, Hubert KAFFL
-
Patent number: 9095691Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: March 15, 2013Date of Patent: August 4, 2015Assignee: Bayer Intellectual Property GmbHInventors: Jochen Schumacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Patent number: 9005653Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: GrantFiled: December 27, 2013Date of Patent: April 14, 2015Assignee: Bayer Intellectual Property GmbHInventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Publication number: 20140109916Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: ApplicationFiled: December 27, 2013Publication date: April 24, 2014Applicant: Bayer Intellectual Property GmbHInventors: Thomas LANGGUTH, Stefan BRACHT, Michael DITTGEN, Petra HUBER, Dirk SCHENK
-
Patent number: 8668925Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: GrantFiled: December 10, 2004Date of Patent: March 11, 2014Assignee: Bayer Intellectual Property GmbHInventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Patent number: 8657986Abstract: A method for producing an active substance-containing polyurethane plaster for transdermal application is described, said plaster containing at least one active substance at a highly accurate declared dose. In the described method, a solvent-free active substance-containing polyurethane is produced by reactively coating a solvent-free active substance-containing polyurethane material (40), which is mixed in a coating unit (60) immediately before or during the application process, onto an elastic backing foil (20) that has been rendered non-extensible at least in the direction in which the applied polyurethane material is processed by means of a supporting, adhering auxiliary foil (30) which is at least mono-axially non-extensible.Type: GrantFiled: November 26, 2009Date of Patent: February 25, 2014Assignee: Otto Bock PUR LifeScience GmbHInventors: Peter Gansen, Michael Dittgen, Ingeborg Steinfatt-Hoffmann, Christian Schulte, Juergen Henze
-
Patent number: 8486443Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: February 4, 2004Date of Patent: July 16, 2013Assignee: Bayer IP GmbHInventors: Jochen Schuhmacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Publication number: 20120083505Abstract: The present invention is directed to an opioid receptor antagonist or a pharmaceutically acceptable salt thereof for use in a method of acute treatment of paraphilic sexual arousal states in patients suffering from paraphilia.Type: ApplicationFiled: June 8, 2010Publication date: April 5, 2012Inventors: Klaus M Beier, Michael Dittgen, Eike Dittgen, Alfred Pauls
-
Publication number: 20110229677Abstract: A method for producing an active substance-containing polyurethane plaster for transdermal application is described, said plaster containing at least one active substance at a highly accurate declared dose. In the described method, a solvent-free active substance-containing polyurethane is produced by reactively coating a solvent-free active substance-containing polyurethane material (40), which is mixed in a coating unit (60) immediately before or during the application process, onto an elastic backing foil (20) that has been rendered non-extensible at least in the direction in which the applied polyurethane material is processed by means of a supporting, adhering auxiliary foil (30) which is at least mono-axially non-extensible.Type: ApplicationFiled: November 26, 2009Publication date: September 22, 2011Inventors: Peter Gansen, Michael Dittgen, Ingeborg Steinfatt-Hoffmann, Christian Chulte, Juergen Henze
-
Publication number: 20060251707Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: February 4, 2004Publication date: November 9, 2006Inventors: Jochen Schumacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Publication number: 20060222708Abstract: The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in the mouth preferably in a period of less than 30 min, and the steroid hormone entering the bloodstream transmucosally from the administration system leads to a rapid rise in the concentration in the blood. It is thus possible to achieve a maximum concentration of this steroid hormone in the blood in a period of less than 60 min after administration.Type: ApplicationFiled: March 28, 2006Publication date: October 5, 2006Inventors: Markus Krumme, Albert Radlmaier, Sascha General, Michael Dittgen, Keith Jensen
-
Patent number: 6977083Abstract: The method of making a bioadhesive tablet for controlling testosterone blood level, especially in elderly men suffering from partial androgen deficiency, includes spray-drying an alcoholic solution or suspension of testosterone and at least one testosterone ester, preferably in a ratio of 1:10 to 1:1.5, separately or together, with an organic polymer and optionally one or more auxiliary ingredient to form an active ingredient premix. Then various other auxiliary ingredients are mixed, as needed, with the active ingredient premix to form the bioadhesive tablet with an active ingredient layer and an adhesive layer. The active ingredient layer contains an effective amount of the active ingredient premix. The adhesive layer includes auxiliary ingredients including the bioadhesive polymer. The bioadhesive tablet may be buccally administered to provide a predetermined timed release profile of testosterone, advantageously varying according to a circadian rhythm.Type: GrantFiled: September 30, 1999Date of Patent: December 20, 2005Assignee: Jenapharm GmbH & Co. KGInventors: Doris Huebler, Guenter Kaufmann, Michael Oettel, Holger Zimmermann, Michael Dittgen, Sabine Fricke, Manfred Boese, Ralf Ladwig, Sven Claussen, Carsten Timpe
-
Publication number: 20050142175Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.Type: ApplicationFiled: December 10, 2004Publication date: June 30, 2005Inventors: Thomas Langguth, Stefan Bracht, Michael Dittgen, Petra Huber, Dirk Schenk
-
Patent number: 6884793Abstract: The combination preparation for contraception includes from 2 to 4 first stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient, from 16 to 22 second stage daily dosage portions each including an effective amount of a combination of at least one natural estrogen and at least one natural or synthetic gestogen as active ingredient; from 2 to 4 third stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient; and from 2 to 4 final stage daily dosage portions containing a pharmaceutically acceptable placebo. The estrogen may be estradiol, an estradiol compound that is metabolized to estradiol when taken into the body, a conjugated equine estrogen or a phytoestrogen. The natural or synthetic gestogen can be natural progesterone or a synthetic gestogens, such as medroxyprogesterone acetate.Type: GrantFiled: September 12, 2001Date of Patent: April 26, 2005Assignee: Jenapharm GmbH & Co. KGInventors: Michael Dittgen, Sabine Fricke, Herbert Hoffmann, Claudia Moore, Michael Oettel, Monika Ostertag
-
Publication number: 20050032756Abstract: A multistage preparation for contraception based on a combination of natural estrogen and synthetic gestogen is described. The preferred preparation contains estradiol valerate as the natural estrogen and dienogest or drospirenone as the synthetic gestogen. In comparison to conventional multistage preparations the multistage preparation according to the invention has a higher contraceptive reliability over the entire cycle, improved cyclic bleeding behavior and minimizes or prevents side effects, such as breast tension, headaches, depressive moods and libido changes.Type: ApplicationFiled: July 15, 2004Publication date: February 10, 2005Inventors: Michael Dittgen, Sabine Fricke, Herbert Hoffmann, Claudia Moore, Michael Oettel, Monika Oster Wald
-
Publication number: 20030044453Abstract: The invention relates to a transdermal therapeutic system for application to the skin and/or mucosa consisting of at least one active substance in the form of a solid dispersion in combination with at least one destructuring agent and/or at least one structuring agent in a common matrix.Type: ApplicationFiled: August 2, 2002Publication date: March 6, 2003Inventors: Michael Dittgen, Sabine Fricke, Christoph Volkel, Kathrin Ahrens, Hagen Gerecke, Kai Kopke
-
Publication number: 20020119103Abstract: A homogeneous steroid-containing preformulation for production of solid and semi-solid pharmaceutical preparations containing a uniform constant dosage of at least one steroid in a range from 0.001 to 1 percent by weight is described. This steroid-containing preformulation contains of from 0.001 to 50 percent by weight of the at least one steroid. The homogeneous steroid-containing preformulation is made by a method including dissolving the at least one steroid in a solvent to form a dispersant; dispersing an adjuvant consisting of adjuvant particles in the dispersant in a mass ratio of the adjuvant to the at least one steroid of 1:1 to 1000:1 to form a suspension; and creating a spray-mist of the suspension so as to evaporate and remove the solvent from the suspension and thus to form a dried particulate which includes steroid-containing particles. The droplets in the spray mist have a droplet diameter greater than a mean diameter of the adjuvant particles.Type: ApplicationFiled: August 27, 2001Publication date: August 29, 2002Inventors: Detlef Grawe, Peter Hoesel, Peter Moellmann, Carsten Timpe, Michael Dittgen, Klaus Matthey